205 related articles for article (PubMed ID: 18025250)
21. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
[TBL] [Abstract][Full Text] [Related]
22. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
Biederman J; Pliszka SR
J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
24. Training raters to assess adult ADHD: reliability of ratings.
Adler LA; Spencer T; Faraone SV; Reimherr FW; Kelsey D; Michelson D; Biederman J
J Atten Disord; 2005 Feb; 8(3):121-6. PubMed ID: 16009660
[TBL] [Abstract][Full Text] [Related]
25. Functional outcomes in the treatment of adults with ADHD.
Adler LA; Spencer TJ; Levine LR; Ramsey JL; Tamura R; Kelsey D; Ball SG; Allen AJ; Biederman J
J Atten Disord; 2008 May; 11(6):720-7. PubMed ID: 17968028
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of the effects of atomoxetine on driving performance in adults with ADHD.
Barkley RA; Anderson DL; Kruesi M
J Atten Disord; 2007 Feb; 10(3):306-16. PubMed ID: 17242426
[TBL] [Abstract][Full Text] [Related]
28. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales.
Murphy KR; Adler LA
J Clin Psychiatry; 2004; 65 Suppl 3():12-7. PubMed ID: 15046530
[TBL] [Abstract][Full Text] [Related]
29. Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability The use of Conners' Adult ADHD Rating Scales (CAARS).
La Malfa G; Lassi S; Bertelli M; Pallanti S; Albertini G
Res Dev Disabil; 2008; 29(2):158-64. PubMed ID: 17416484
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
31. Self-reported childhood attention-deficit/hyperactivity disorder symptoms are not specific to the disorder.
Suhr J; Zimak E; Buelow M; Fox L
Compr Psychiatry; 2009; 50(3):269-75. PubMed ID: 19374973
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder.
Manor I; Newcorn JH; Faraone SV; Adler LA
Postgrad Med; 2013 Jul; 125(4):181-90. PubMed ID: 23933905
[TBL] [Abstract][Full Text] [Related]
33. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.
Biederman J; Mick E; Faraone S; Hammerness P; Surman C; Harpold T; Dougherty M; Aleardi M; Spencer T
J Clin Psychopharmacol; 2006 Apr; 26(2):163-6. PubMed ID: 16633145
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
35. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
Spencer TJ; Faraone SV; Michelson D; Adler LA; Reimherr FW; Glatt SJ; Biederman J
J Clin Psychiatry; 2006 Mar; 67(3):415-20. PubMed ID: 16649828
[TBL] [Abstract][Full Text] [Related]
36. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
Brod M; Adler LA; Lipsius S; Tanaka Y; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2015 Jun; 7(2):141-50. PubMed ID: 25563210
[TBL] [Abstract][Full Text] [Related]
37. Psychometric properties of an adult ADHD diagnostic interview.
Epstein JN; Kollins SH
J Atten Disord; 2006 Feb; 9(3):504-14. PubMed ID: 16481667
[TBL] [Abstract][Full Text] [Related]
38. Validity of self-report and informant rating scales of adult ADHD symptoms in comparison with a semistructured diagnostic interview.
Magnússon P; Smári J; Sigurdardóttir D; Baldursson G; Sigmundsson J; Kristjánsson K; Sigurdardóttir S; Hreidarsson S; Sigurbjörnsdóttir S; Gudmundsson OO
J Atten Disord; 2006 Feb; 9(3):494-503. PubMed ID: 16481666
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a scale to assess the symptoms of attention-deficit/hyperactivity disorder in young adults.
Caterino LC; Gómez-Benito J; Balluerka N; Amador-Campos JA; Stock WA
Psychol Assess; 2009 Jun; 21(2):152-61. PubMed ID: 19485670
[TBL] [Abstract][Full Text] [Related]
40. Reliability of DSM-IV Symptom Ratings of ADHD: implications for DSM-V.
Solanto MV; Alvir J
J Atten Disord; 2009 Sep; 13(2):107-16. PubMed ID: 19372494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
